You have free access to this content

Cancer

Cover image for Cancer

1 January 2001

Volume 91, Issue 1

Pages 1–188

  1. Original Article

    1. Top of page
    2. Original Article
    1. Disease Site

      Breast Disease
      You have free access to this content
      Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality (pages 1–8)

      Ron Allison, Tom Mang, Gretchen Hewson, Wendy Snider and David Dougherty

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<1::AID-CNCR1>3.0.CO;2-P

      Chest wall recurrence from breast carcinoma has few therapeutic options. Photodynamic therapy may play an important role.

    2. You have free access to this content
      Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ (pages 9–16)

      Kai C. Chan, W. Fiona Knox, Guria Sinha, Ashu Gandhi, Lester Barr, Andrew D. Baildam and Nigel J. Bundred

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<9::AID-CNCR2>3.0.CO;2-E

      Tumor free excision margins greater than 1 mm regardless of width of clearance were associated with a low recurrence rate after breast conserving surgery for ductal carcinoma in situ. Adjuvant radiotherapy and/or tamoxifen did not compensate for close excision margins (≤ 1 mm).

    3. You have free access to this content
      Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma (pages 17–24)

      Arnold F. Jacobson, Charles L. Shapiro, Annick D. Van den Abbeele and William D. Kaplan

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<17::AID-CNCR3>3.0.CO;2-K

      Among patients with breast carcinoma with initial distant recurrence in bone only, those with bone scan findings of only one or two lesions have a significant survival advantage over patients with scans showing three or more new abnormalities. Patients in the latter category have no survival advantage compared with individuals with metastatic involvement at other visceral sites.

    4. You have free access to this content
      Reduction in fat intake is not associated with weight loss in most women after breast cancer diagnosis : Evidence from a randomized controlled trial (pages 25–34)

      Cheryl L. Rock, Cynthia Thomson, Bette J. Caan, Shirley W. Flatt, Vicky Newman, Cheryl Ritenbaugh, James R. Marshall, Kathryn A. Hollenbach, Marcia L. Stefanick and John P. Pierce

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<25::AID-CNCR4>3.0.CO;2-G

      The current study hypothesized that examining the effect of a low fat, high vegetable diet on risk for recurrence of breast cancer is unlikely to be confounded by weight loss in subjects who are the recipients of these diet intervention efforts. Increased intakes of fiber and vegetables were the dietary factors most strongly associated with weight loss in the women under study, although minimal weight change occurred.

    5. Endocrine Disorders
      You have free access to this content
      Preoperative diagnosis of intraductal papillary-mucinous tumors of the pancreas with attention to telomerase activity (pages 35–41)

      Hiroki Inoue, Akira Tsuchida, Yousuke Kawasaki, Yoshifumi Fujimoto, Souichirou Yamasaki and Goro Kajiyama

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<35::AID-CNCR5>3.0.CO;2-A

      Telomerase activity using pancreatic juice is more accurate than conventional cytologic examination in differentiating adenoma from carcinoma of intraductal papillary-mucinous tumor of the pancreas.

    6. You have free access to this content
      Frequent nuclear accumulation of β-catenin in pituitary adenoma (pages 42–48)

      Shuho Semba, Shuang-Yin Han, Hidetoshi Ikeda and Akira Horii

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<42::AID-CNCR6>3.0.CO;2-7

      Frequent (57%) nuclear accumulation of β-catenin (CTNNB1) was detected in pituitary adenoma, and was found to be correlated closely with Ki-67 proliferative activity. In addition, somatic mutations in exon 3 of the CTNNB1 gene also were detected. It has been suggested that activation of the Wnt signaling pathway including CTNNB1 may play an important role in tumorigenesis in the pituitary gland.

    7. Gastrointestinal Tract
      You have free access to this content
      Comparison of MALT and non-MALT primary large cell lymphoma of the stomach : Does histologic evidence of MALT affect chemotherapy response? (pages 49–56)

      Chiun Hsu, Chi-Long Chen, Li-Tzong Chen, Han-Ting Liu, Yao-Chang Chen, Chang-Ming Jan, Chiang-Shin Liu and Ann-Lii Cheng

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<49::AID-CNCR7>3.0.CO;2-Y

      In this retrospective study, patients who had been diagnosed with primary large cell lymphoma of the stomach and had received chemotherapy as their first line of therapy were formed into two groups based upon the presence or absence of histologic features of MALToma (lymphoma of mucosa-associated lymphoid tissue). Study results suggested that the presence of histologic features of MALToma might have been associated with a better response to systemic chemotherapy and a better prognosis.

    8. You have free access to this content
      Genetic testing for colorectal carcinoma susceptibility : Focus group responses of individuals with colorectal carcinoma and first-degree relatives (pages 57–65)

      Anita Y. Kinney, Brenda M. DeVellis, Cecile Skrzynia and Robert Millikan

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<57::AID-CNCR8>3.0.CO;2-U

      Focus group methodology was used to assess attitudes toward genetic testing among patients with colorectal carcinoma and first-degree relatives. Perceived benefits and drawbacks of testing, informational needs, family communication issues, and decision-making factors are reported.

    9. Genitourinary Disease
      You have free access to this content
      Risk of prostate carcinoma death in patients with lymph node metastasis (pages 66–73)

      Liang Cheng, Horst Zincke, Michael L. Blute, Erik J. Bergstralh, Beth Scherer and David G. Bostwick

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P

      In an analysis of 3463 patients at the Mayo Clinic with carcinoma of the prostate, it was found that patients with multiple regional lymph node metastases were at increased risk of cancer death, whereas patients with a single involved lymph node appeared to have a more favorable prognosis after radical prostatectomy and immediate adjuvant hormonal therapy. By combining surgery and adjuvant hormonal therapy, excellent local disease control was achieved in lymph node positive patients.

    10. Gynecologic Oncology
      You have free access to this content
      Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma (pages 74–79)

      Susumu Adachi, Toshitada Ogasawara, Eiko Wakimoto, Yoshiyuki Tsuji, Tadashi Takemura, Koji Koyama, Yukio Takayasu, Jyunn-ichi Inoue and Norio Nakao

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<74::AID-CNCR10>3.0.CO;2-6

      Nedaplatin, a platinum analogue with less renal toxicity and similar efficacy for cervical carcinoma, has a synergistic effect on cervical carcinoma cell lines in combination with cisplatin. The authors conducted a Phase I/II Study of intravenous nedaplatin and intranveous cisplatin in combination with transcatheter arterial embolization and obtained a response rate of 100% in patients with locally advanced cervical carcinoma.

    11. You have free access to this content
      The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with Stage IIIB cervical carcinoma treated with radiation therapy alone (pages 80–89)

      Hitoshi Ishikawa, Norio Mitsuhashi, Hideyuki Sakurai, Katsuya Maebayashi and Hideo Niibe

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<80::AID-CNCR11>3.0.CO;2-E

      This analysis of patients with International Federation of Gynecology and Obstetrics Stage IIIB squamous cell carcinoma of the cervix who were treated with radiation therapy alone suggests that there are significant differences in the recurrence free survival rate and local control rate according to the p53 status of the patient. It is possible that the p53 gene may be used as a predictive factor in radiation therapy for patients with cervical carcinoma.

    12. You have free access to this content
      Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin : Analysis of toxicities and predictors of outcome (pages 90–100)

      Tamar Safra, Susan Groshen, Susan Jeffers, Denice D. Tsao-Wei, Linyun Zhou, Laila Muderspach, Lynda Roman, C. Paul Morrow, Alexander Burnett and Franco M. Muggia

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A

      An analysis of patient characteristics was performed in relation to outcome after the administration of pegylated liposomal doxorubicin to patients with ovarian carcinoma. Tumor size, baseline hemoglobin level, and Karnofsky performance status were the main predictive factors for survival, and tumor size and baseline hemoglobin level were the main predictive factors for the time to treatment failure.

    13. Hepatobiliary Tract
      You have free access to this content
      A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma (pages 101–105)

      Eileen M. O'Reilly, Keith E. Stuart, Pedro M. Sanz-Altamira, Gary K. Schwartz, Carolyn M. Steger, Lynn Raeburn, Nancy E. Kemeny, David P. Kelsen and Leonard B. Saltz

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K

      A Phase II clinical trial of irinotecan in patients who had locally advanced, recurrent, or metastatic hepatoma was conducted. Only modest activity and significant toxicity were observed. Single agent irinotecan was not recommended by the current study results for palliation of advanced hepatocellular cancer.

    14. You have free access to this content
      Expression of c-Myc, c-Fos, and c-Jun in hepatocellular carcinoma (pages 106–112)

      Man-Fung Yuen, Pui-Chee Wu, Vicky Ching-Har Lai, Johnson Yiu-Nam Lau and Ching-Lung Lai

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2

      This study showed that the expression of c-myc in hepatoma cells was relatively diminished. The resulting decreased apoptosis may lead to the uncoordinated control of cellular growth and, hence, may contribute to hepatocarcinogenesis. The role of increased expressions of c-fos and c-jun in the process of hepatocarcinogenesis remains to be elucidated.

    15. Lung Disease
      You have free access to this content
      Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease–nonobese diabetic mice : Relation with interleukin-10 induction (pages 113–122)

      Carine Asselin-Paturel, Smaïl Megherat, Isabelle Vergnon, Hamid Echchakir, Guillaume Dorothée, Sévrine Blesson, Françoise Gay, Fathia Mami-Chouaib and Salem Chouaib

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<113::AID-CNCR15>3.0.CO;2-7

      This report demonstrates that, in contrast with low doses of human interleukin (IL)-12, high doses have no effect on the growth of human lung tumors engrafted into severe combined immunodeficiency disease–nonobese diabetic mice, and adoptively transferred with a specific autologous cytotoxic cell line. The authors' data indicate that IL-10 may play a critical role in the lack of effect of high dose IL-12, by mediating tumor cell resistance to cytotoxic T lymphocyte killing.

    16. You have free access to this content
      Combined choriocarcinoma and adenocarcinoma of the lung occurring in a man : Case report and review of the literature (pages 123–129)

      Fengshi Chen, Akitoshi Tatsumi and Satoshi Numoto

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<123::AID-CNCR16>3.0.CO;2-3

      Primary pulmonary choriocarcinoma occurring in a man is an extremely rare entity. In the current study the authors report their experience with combined choriocarcinoma and adenocarcinoma of the lung diagnosed in a man and review the previously reported cases.

    17. Neuro-Oncology
      You have free access to this content
      Primary central nervous system lymphoma 1991–1997 : Outcome and late adverse effects after combined modality treatment (pages 130–135)

      Ulrich Herrlinger, Martin Schabet, Wolfram Brugger, Rolf-Dieter Kortmann, Lothar Kanz, Michael Bamberg, Johannes Dichgans and Michael Weller

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<130::AID-CNCR17>3.0.CO;2-8

      Combined modality therapy (methotrexate, radiotherapy, cytarabine) that could be administered only to a subgroup of 28 consecutive patients with primary central nervous system lymphoma led to prolonged survival in these patients but was associated with a high rate of late neurotoxicity.

    18. You have free access to this content
      Central neurocytomas express photoreceptor differentiation (pages 136–143)

      Hernando Mena, Alan L. Morrison, Robert V. Jones and Kymberly A. Gyure

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<136::AID-CNCR18>3.0.CO;2-O

      Central neurocytomas are low grade neoplasms that generally display no evidence of malignant transformation. The neoplastic cells may express divergent differentiation including photoreceptor, neuronal, and glial. Mesenchymal (adipocyte) differentiation also may be present. Central neurocytomas therefore may be morphologically related to pineocytomas and possibly to cerebellar liponeurocytoma.

    19. Discipline

      Medical Oncology
      You have free access to this content
      A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease (pages 144–154)

      James R. Berenson, Robert Vescio, Kathryn Henick, Carol Nishikubo, Matthew Rettig, Regina A. Swift, Francisco Conde and Joseph M. Von Teichert

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q

      In a Phase I trial in cancer patients with metastatic bone disease, zoledronic acid, a highly potent, nitrogen-containing bisphosphonate administered intravenously, was safe and well tolerated and effectively suppressed markers of bone resorption. The authors believe zoledronic acid may improve the treatment of metastatic bone disease.

    20. You have free access to this content
      Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma (pages 155–163)

      Emanuela Vaccher, Michele Spina, Giampiero di Gennaro, Renato Talamini, Guglielmo Nasti, Ornella Schioppa, Giuseppe Vultaggio and Umberto Tirelli

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B

      The authors provide data on a group of patients with human immunodeficiency virus (HIV)-related lymphoma who were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus highly active antiretroviral therapy. These data are compared with data from historic control patients who received CHOP chemotherapy alone. The question is addressed of the best approach for combining treatment in patients with lymphoma and HIV infection.

    21. Epidemiology
      You have free access to this content
      Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City (pages 164–172)

      Alfred R. Ashford, Steven M. Albert, Gerald Hoke, Linda F. Cushman, Daniel S. Miller and Mary Bassett

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<164::AID-CNCR21>3.0.CO;2-A

      In a combined clinic and telephone-based survey of men aged 50–74 years, less than a quarter of African-American men in Central Harlem reported having a prostate specific antigen (PSA) test to screen for prostate carcinoma, a rate lower than that reported for other populations at less risk for the disease. Favorable attitudes toward screening and knowing someone with prostate carcinoma were associated with self-reported PSA screening, but clinic and community samples differed in these relations, suggesting a need for more sensitive targeting of health promotion campaigns.

    22. Pathology
      You have free access to this content
      Mammotome core biopsy for mammary microcalcification : Analysis of 160 biopsies from 142 women with surgical and radiologic followup (pages 173–177)

      Joan Cangiarella, Jerry Waisman, W. Fraser Symmans, Joshua Gross, Jean-Marc Cohen, Horace Wu and Deborah Axelrod

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<173::AID-CNCR22>3.0.CO;2-9

      Mammotome biopsy proved to be an accurate technique for the sampling and diagnosis of mammary microcalcification.

    23. You have free access to this content
      Disparities in cancer diagnosis and survival (pages 178–188)

      Cathy J. Bradley, Charles W. Given and Caralee Roberts

      Article first published online: 4 JAN 2001 | DOI: 10.1002/1097-0142(20010101)91:1<178::AID-CNCR23>3.0.CO;2-S

      The authors showed that the disparities in cancer outcomes may be greater than previously thought and are consistent across cancer site. If advancements made in cancer control are to be shared by the low-income population, then improvements clearly are needed in cancer prevention, early detection, and treatment for the poor.

SEARCH

SEARCH BY CITATION